Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2022 1
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Heterogeneity and treatment landscape of ovarian carcinoma.
Veneziani AC, Gonzalez-Ochoa E, Alqaisi H, Madariaga A, Bhat G, Rouzbahman M, Sneha S, Oza AM. Veneziani AC, et al. Among authors: gonzalez ochoa e. Nat Rev Clin Oncol. 2023 Dec;20(12):820-842. doi: 10.1038/s41571-023-00819-1. Epub 2023 Oct 2. Nat Rev Clin Oncol. 2023. PMID: 37783747 Review.
Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer.
Gonzalez-Ochoa E, Veneziani AC, Oza AM. Gonzalez-Ochoa E, et al. Clin Med Insights Oncol. 2023 Jul 25;17:11795549231187264. doi: 10.1177/11795549231187264. eCollection 2023. Clin Med Insights Oncol. 2023. PMID: 37528890 Free PMC article. Review.
Systemic therapy for non-serous ovarian carcinoma.
Chávarri-Guerra Y, González-Ochoa E, De-la-Mora-Molina H, Soto-Perez-de-Celis E. Chávarri-Guerra Y, et al. Among authors: gonzalez ochoa e. Chin Clin Oncol. 2020 Aug;9(4):52. doi: 10.21037/cco-20-36. Epub 2020 Jul 28. Chin Clin Oncol. 2020. PMID: 32787339 Free article. Review.
Emerging peptide therapeutics for the treatment of ovarian cancer.
Veneziani AC, Gonzalez-Ochoa E, Oza AM. Veneziani AC, et al. Among authors: gonzalez ochoa e. Expert Opin Emerg Drugs. 2023 Dec;28(2):129-144. doi: 10.1080/14728214.2023.2218643. Epub 2023 Jun 7. Expert Opin Emerg Drugs. 2023. PMID: 37282529 Review.
Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression.
Lheureux S, Prokopec SD, Oldfield LE, Gonzalez-Ochoa E, Bruce JP, Wong D, Danesh A, Torti D, Torchia J, Fortuna A, Singh S, Irving M, Marsh K, Lam B, Speers V, Yosifova A, Oaknin A, Madariaga A, Dhani NC, Bowering V, Oza AM, Pugh TJ. Lheureux S, et al. Among authors: gonzalez ochoa e. Clin Cancer Res. 2023 Sep 15;29(18):3706-3716. doi: 10.1158/1078-0432.CCR-23-0797. Clin Cancer Res. 2023. PMID: 37327320 Free PMC article. Clinical Trial.
A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers.
Gonzalez-Ochoa E, Milosevic M, Corr B, Abbruzzese JL, Girda E, Miller RW, Croke J, Mackay H, Lee YC, Bowering V, Ramsahai J, Wang L, D'Souza A, Kunos CA, Oza AM, Lheureux S. Gonzalez-Ochoa E, et al. Int J Gynecol Cancer. 2023 Aug 7;33(8):1208-1214. doi: 10.1136/ijgc-2023-004491. Int J Gynecol Cancer. 2023. PMID: 37380217 Free PMC article. Clinical Trial.
Electronic malignant bowel obstruction symptom monitoring smartphone application for patients with gynecologic cancers.
Madariaga A, Jivraj N, Soberanis Pina P, Somji F, Truong T, Melwani S, Lovas M, Gogos TA, Sajewycz K, Bhat G, Alqaisi H, Gonzalez-Ochoa E, Veneziani A, Garg V, Dhani NC, Grant R, Bowering V, Oza AM, Wang L, Berlin A, Lheureux S. Madariaga A, et al. Among authors: gonzalez ochoa e. Int J Gynecol Cancer. 2024 May 31:ijgc-2024-005490. doi: 10.1136/ijgc-2024-005490. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 38821545
11 results